Literature DB >> 17295848

Review article: bacterial flora and pathogenesis in hepatic encephalopathy.

R Williams1.   

Abstract

The aetiology of hepatic encephalopathy has not been conclusively established, but it is widely agreed that ammonia derived primarily from enteric bacterial flora plays a central role. Recent research on the pathogenesis of hepatic encephalopathy reinforces previous findings, supporting an integral role of bacteria-derived ammonia and reveals other potential mechanisms by which bacterial flora and pathogens may be pathophysiologically important. This review discusses this research and considers its implications for the therapeutic management of hepatic encephalopathy. Besides producing ammonia, the enteric flora generates other neurotoxic products, such as phenols and mercaptans, that may potentiate the effects of ammonia. Bacteria may also constitute a primary source of the benzodiazepine-like compounds implicated in neuropsychiatric symptoms in patients with liver disease. New evidence suggests that acute bacterial infections, long recognized as important precipitants of hepatic encephalopathy, may mediate clinical worsening through effects on systemic inflammatory responses. Considered together, these data suggest wide-ranging pathophysiological contributions of bacteria to hepatic encephalopathy and underline the potential for an integral role of antibiotics and other bactericidal agents in its management.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17295848     DOI: 10.1111/j.1746-6342.2006.03217.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.

Authors:  Haifeng Lu; Zhongwen Wu; Wei Xu; Jiezuan Yang; Yunbo Chen; Lanjuan Li
Journal:  Microb Ecol       Date:  2011-02-01       Impact factor: 4.552

Review 2.  Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature.

Authors:  Nathaniel Aviv Cohen; Nitsan Maharshak
Journal:  Dig Dis Sci       Date:  2017-03-17       Impact factor: 3.199

3.  Daily ciprofloxacin treatment for patients with advanced liver disease awaiting liver transplantation reduces hospitalizations.

Authors:  G Y Minuk; K Hawkins; K D E Kaita; S Wong; E Renner; L Minuk; J Uhanova
Journal:  Dig Dis Sci       Date:  2010-11-06       Impact factor: 3.199

4.  Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α.

Authors:  Pierre Deltenre; Christian Labenz; Marcus Schuchmann
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

Review 5.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 6.  Hepatic encephalopathy: Ever closer to its big bang.

Authors:  Pablo A Souto; Ariel R Marcotegui; Lisandro Orbea; Juan Skerl; Juan Carlos Perazzo
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

7.  Probiotics, prebiotics, and synbiotics: gut and beyond.

Authors:  Usha Vyas; Natarajan Ranganathan
Journal:  Gastroenterol Res Pract       Date:  2012-09-19       Impact factor: 2.260

Review 8.  Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.

Authors:  Mark Hudson; Marcus Schuchmann
Journal:  Eur J Gastroenterol Hepatol       Date:  2019-04       Impact factor: 2.566

9.  Hydrogen Sulfide Protects Against Ammonia-Induced Neurotoxicity Through Activation of Nrf2/ARE Signaling in Astrocytic Model of Hepatic Encephalopathy.

Authors:  Xiaozhi Jin; Dazhi Chen; Faling Wu; Lei Zhang; Yu Huang; Zhuo Lin; Xiaodong Wang; Rui Wang; Lanman Xu; Yongping Chen
Journal:  Front Cell Neurosci       Date:  2020-10-22       Impact factor: 5.505

10.  Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-α (PROSPER): an observational study among 550 patients.

Authors:  Aleksander Krag; Marcus Schuchmann; Hanna Sodatonou; Jeff Pilot; James Whitehouse; Simone I Strasser; Mark Hudson
Journal:  Hepatol Med Policy       Date:  2018-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.